U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938580) titled 'Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia' on Nov. 09.

Brief Summary: This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Myelofibrosis

Intervention: DRUG: Gecacitinib

Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be bas...